<DOC>
	<DOC>NCT00368134</DOC>
	<brief_summary>This study is designed to evaluate the efficacy, safety and tolerability of vildagliptin compared to voglibose in patients with type 2 diabetes. Please note this study is not being conducted in the United States.</brief_summary>
	<brief_title>To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<criteria>Diagnosis as Type 2 Diabetes Patients who have been placed on dietary therapy/exercise therapy, without achievement of glycemic control Outpatients Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes Significant heart diseases Significant diabetic complications Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>